Researchers evaluated protection conferred by a single COVID-19 mRNA vaccine dose vs a 2-dose series in the setting of high preexisting SARS-CoV-2 immunity.

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

COVID-19 vaccination is associated with a reduced risk for most CV events, but with slightly increased risks for extrasystoles and transient ischemic attack, as well as myocarditis and pericarditis ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...

COVID-19 2024–2025 vaccines are recommended for everyone aged 6 months and older, with vaccines targeting the JN.1 and KP.2 strains of SARS-CoV-2.

The UK Government has recommended offering a COVID-19 booster vaccination in autumn, 2024, to individuals at high risk of ...

We recently published a list of 10 Best Depressed Stocks To Buy Heading into 2025. In this article, we are going to take a ...

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid ...

A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides ...

Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle ...